A Phase II, Randomized, Open-Label Study of Single Agent CI-1033 in Patients With Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2009
At a glance
- Drugs Canertinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 01 Nov 2009 Results reported in Cancer Chemotherapy and Pharmacology.
- 24 Nov 2006 New trial record.